Clinicl Research Of Advanced Non-small Cell Lung Cancer Pantients Treated With DC And CIK Cells Immunotherapy Combined With Chemotherapy

Objective: To investigate the effect of autologous dendritic cells (DC) andcytokine induced killer (CIK) cells immunotherapy combined withchemotherapy of advanced non-small cell lung cancer（NSCLC）（DC+CIK-chemotherapy）patients.Methods: Chose168cases of patients with advanced NSCLC, the84advancedNSCLC patients who treated with DC+CIK-chemotherapy was taken astreatment group, and the another84advanced NSCLC patients who only treatedwith chemotherapy as control group. The term efficacy、the change of theratios of lymphocyte phenotype and the quality of life of the two groups werecompared. Then we analyzed whether the clinical characteristics of patientswould impact the term efficacy of DC+CIK-chemotherapy or not, and adversereactions were observed to assess its safety after patients were infused by DCand CIK cells. Results:(1) The response rates of the treatment group and the control groupwere48.81%vs36.90%(P>0.05), and the disease control rates were66.67%vs51.19%(P<0.05).(2) The result of compared peripheral blood lymphocytephenotype of patients before and after treatment show that:①Comparedbetween the two groups: Before treatment the differences of the ratio of CD4+、CD8+、NK cells and CD4+/CD8+of two groups showed no statisticallysignificant (P>0.05); After treatment the ratio of CD4+、NK cells andCD4+/CD8+of the treatment group were higher than the control group, thedifferences showed statistically significant (p<0.05),while the ratio of CD8+cells was decreased (P>0.05);②Compared within two groups: the ratios ofCD4+、NK cells and CD4+/CD8+of the treatment group after treatment wereincreased, the ratio of CD8+cells was decreased, all the differences showedstatistically significant (P<0.05), but the ratio of CD4+、CD8+、NK cells andCD4+/CD8+of the control group after treatment were decreased, just thedifference of CD4+/CD8+show no statistically significant (p>0.05);(3) Theresponse rate and disease control rate of the patients with KPS score≥80points,locally advanced, and the size of tumor≦3cm are higher than the patients withKPS score＜80points, metastasis, and the size of tumor>3cm (P<0.05).(4)Thesymptoms of poor spirit, anorexia, fatigue and KPS score of the treatment groupwas significantly improved compared with the control group (P<0.05).Only7patients with low-grade fever were observed after infused with DC and CIKcells. Conclusions: DC+CIK-chemotherapy can enhance the disease control rate ofpatients with advanced NSCLC, and enhance the ratio of CD4+cells and theratio of NK cells, and improve the immune function and the quality of life ofpatients without any serious side effects, but the KPS score, clinical staging andthe size of tumor will affect its efficacy.